Treatment of Graves´ ophthalmopathy with diclofenak or simvastatin - GO-DS

Department of Endocrinology0 个研究点目标入组 102 人开始时间: 2015年11月30日最近更新: 2016年3月14日

试验速览

暂无简介。

•1.Age 18-70 years
•2.Active mild to moderate with at least one sign of mild GO (NO SPECS class 2a and b) with reference to Colour Atlas at EUGOGO website (www.eugogo.eu). Exophthalmos up to 24 mm with a disease duration of <18 months (as recorded by the patient)
•3.a. Graves´ disease with clinical and laboratory euthyroidism after stopping treatment with anti thyroid drugs (ATD)
•b. or 2 months treatment with ATD
•c. or euthyroid 6 months after treatment with radioiodine
•d. or euthyroid after total thyroidectomy.
•Clinical and laboratory euthyroidism is defined as normal fT4, fT3 and TSH below the upper limit of the local reference interval (Malmö 3.7, Odense? Århus 4.3) and no clinical symtoms or signs of hyperthyroidism. L-thyroxine is used to achieve euthyroidism during the study period.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 92
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1.Pregnancy or breast-feeding
•2.Previous treatment for GO
•3.Severe GO requiering corticosteroid treatment, retrobulbar irradiation, orbital or decompression surgery
•4.Current or previous treatment with diclofenak (within 3 months for more than 7 consecutive days) or simvastatin or other statins (within 3 months)
•5.Allergy (skin rash or systemic reactions) to NSAID, ASA or statins
•6.Congestive heart failure
•7.Renal insufficiency (glomerular filtration rate <60 ml/min)
•8.ASAT or ALAT > 2.5 times the upper limit of the local laboratory
•9.Alcoholism as judged by local criteria
•10.Coagulopathy including treatment with warfarin or new oral anti-coagulation drugs
•11.Previous or current gastric ulcer
•12.Inflammatory bowel disease diabetic retinopathy or nephropathy
•13.Trauma within 10 Days

发起方